277 related articles for article (PubMed ID: 28494404)
1. Treatment and pattern of bone metastases in 1094 patients with advanced breast cancer - Results from the prospective German Tumour Registry Breast Cancer cohort study.
Schröder J; Fietz T; Köhler A; Petersen V; Tesch H; Spring L; Fleitz A; Jänicke M; Marschner N;
Eur J Cancer; 2017 Jul; 79():139-148. PubMed ID: 28494404
[TBL] [Abstract][Full Text] [Related]
2. Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer - Results from the prospective German TMK cohort study.
Fietz T; Tesch H; Rauh J; Boller E; Kruggel L; Jänicke M; Marschner N;
Breast; 2017 Aug; 34():122-130. PubMed ID: 28586735
[TBL] [Abstract][Full Text] [Related]
3. Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours.
Zheng GZ; Chang B; Lin FX; Xie D; Hu QX; Yu GY; Du SX; Li XD
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 27430483
[TBL] [Abstract][Full Text] [Related]
4. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study.
Scagliotti GV; Hirsh V; Siena S; Henry DH; Woll PJ; Manegold C; Solal-Celigny P; Rodriguez G; Krzakowski M; Mehta ND; Lipton L; García-Sáenz JA; Pereira JR; Prabhash K; Ciuleanu TE; Kanarev V; Wang H; Balakumaran A; Jacobs I
J Thorac Oncol; 2012 Dec; 7(12):1823-1829. PubMed ID: 23154554
[TBL] [Abstract][Full Text] [Related]
5. Different patterns of change in bone turnover markers during treatment with bone-modifying agents for breast cancer patients with bone metastases.
Nishimukai A; Higuchi T; Ozawa H; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Miyoshi Y
Breast Cancer; 2017 Mar; 24(2):245-253. PubMed ID: 27040403
[TBL] [Abstract][Full Text] [Related]
6. Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid.
von Moos R; Body JJ; Egerdie B; Stopeck A; Brown JE; Damyanov D; Fallowfield LJ; Marx G; Cleeland CS; Patrick DL; Palazzo FG; Qian Y; Braun A; Chung K
Support Care Cancer; 2013 Dec; 21(12):3497-507. PubMed ID: 23975226
[TBL] [Abstract][Full Text] [Related]
7. Impact of denosumab use on the survival of untreated non-squamous non-small cell lung cancer patients with bone metastases.
Udagawa H; Niho S; Kirita K; Umemura S; Matsumoto S; Yoh K; Goto K
J Cancer Res Clin Oncol; 2017 Jun; 143(6):1075-1082. PubMed ID: 28220258
[TBL] [Abstract][Full Text] [Related]
8. Bone targeted therapies in advanced breast cancer.
Biskup E; Cai F; Vetter M
Swiss Med Wkly; 2017 Jul; 147():w14440. PubMed ID: 28695563
[TBL] [Abstract][Full Text] [Related]
9. Uptake of bone-modifying agents in patients with HER2+ metastatic breast cancer with bone metastases - prospective data from a multi-site Australian registry.
Wong V; de Boer R; Dunn C; Anton A; Malik L; Greenberg S; Yeo B; Nott L; Collins IM; Torres J; Barnett F; Nottage M; Gibbs P; Lok SW
Intern Med J; 2022 Oct; 52(10):1707-1716. PubMed ID: 34002929
[TBL] [Abstract][Full Text] [Related]
10. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
Henry DH; Costa L; Goldwasser F; Hirsh V; Hungria V; Prausova J; Scagliotti GV; Sleeboom H; Spencer A; Vadhan-Raj S; von Moos R; Willenbacher W; Woll PJ; Wang J; Jiang Q; Jun S; Dansey R; Yeh H
J Clin Oncol; 2011 Mar; 29(9):1125-32. PubMed ID: 21343556
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.
Coleman R; Cameron D; Dodwell D; Bell R; Wilson C; Rathbone E; Keane M; Gil M; Burkinshaw R; Grieve R; Barrett-Lee P; Ritchie D; Liversedge V; Hinsley S; Marshall H;
Lancet Oncol; 2014 Aug; 15(9):997-1006. PubMed ID: 25035292
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.
Jacobs C; Kuchuk I; Bouganim N; Smith S; Mazzarello S; Vandermeer L; Dranitsaris G; Dent S; Gertler S; Verma S; Song X; Simos S; Cella D; Clemons M
Breast Cancer Res Treat; 2016 Jan; 155(1):77-84. PubMed ID: 26643085
[TBL] [Abstract][Full Text] [Related]
13. Validity of bone marker measurements for monitoring response to bisphosphonate therapy with zoledronic acid in metastatic breast cancer.
Aktas B; Kasimir-Bauer S; Lehmann N; Kimmig R; Tewes M
Oncol Rep; 2013 Jul; 30(1):441-7. PubMed ID: 23604361
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic approaches for protecting bone health in patients with breast cancer.
Lüftner D; Niepel D; Steger GG
Breast; 2018 Feb; 37():28-35. PubMed ID: 29073497
[TBL] [Abstract][Full Text] [Related]
15. Routine treatment and outcome of breast cancer in younger versus elderly patients: results from the SENORA project of the prospective German TMK cohort study.
Fietz T; Zahn MO; Köhler A; Engel E; Frank M; Kruggel L; Jänicke M; Marschner N;
Breast Cancer Res Treat; 2018 Jan; 167(2):567-578. PubMed ID: 29030786
[TBL] [Abstract][Full Text] [Related]
16. Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases.
Niikura N; Liu J; Hayashi N; Palla SL; Tokuda Y; Hortobagyi GN; Ueno NT; Theriault RL
Cancer; 2012 Apr; 118(8):2039-47. PubMed ID: 22139648
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
[TBL] [Abstract][Full Text] [Related]
18. TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis.
Mitri Z; Nanda R; Blackwell K; Costelloe CM; Hood I; Wei C; Brewster AM; Ibrahim NK; Koenig KB; Hortobagyi GN; Van Poznak C; Rimawi MF; Moulder-Thompson S;
Clin Cancer Res; 2016 Dec; 22(23):5706-5712. PubMed ID: 27166393
[TBL] [Abstract][Full Text] [Related]
19. Bone modifying agents for patients with bone metastases from breast cancer managed in routine practice setting: Treatment patterns and outcome.
Zekri J; Farag K; Yousof O; Zabani Y; Mohamed W; Ahmed GA
J Oncol Pharm Pract; 2020 Jun; 26(4):906-911. PubMed ID: 31575357
[TBL] [Abstract][Full Text] [Related]
20. Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents.
Lipton A; Smith MR; Fizazi K; Stopeck AT; Henry D; Brown JE; Shore ND; Saad F; Spencer A; Zhu L; Warner DJ
Clin Cancer Res; 2016 Dec; 22(23):5713-5721. PubMed ID: 27140926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
